BRISTOL-MYERS SQUIBB COMPANY (CELG-RI) discovers, develops, or markets pharmaceutical products. CELG-RI stock sits in Health Care (Pharmaceutical Preparations), listed on NYSE.

BRISTOL-MYERS SQUIBB COMPANY financial statements — income statement, balance sheet, and cash flow — are on this CELG-RI stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.

This page is a research snapshot of BRISTOL-MYERS SQUIBB COMPANY (CELG-RI) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.

The live chart on this CELG-RI stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.

BRISTOL-MYERS SQUIBB COMPANY is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on NYSE. This page is a research snapshot, not a full company profile.

Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.

Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.

On this CELG-RI stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.

CELG-RI stock currently scores 55/100 (Watch / incomplete (<60)). BRISTOL-MYERS SQUIBB COMPANY scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.

Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.

Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.

A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.

No recommendation either way. This CELG-RI stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell BRISTOL-MYERS SQUIBB COMPANY.